Market LIVE
Published markets; coverage varies by country
Product profile · United States

COSELA

 ·  Patent Litigation & Settlement History ↓

IngredientTRILACICLIB DIHYDROCHLORIDE
Application typeNDA
Application214200
Product001
Dosage formPOWDER
RouteINTRAVENOUS
StrengthEQ 300MG BASE/VIAL
Approval date2021-02-12
Marketing statusPrescription
Status event—
ApplicantPHARMACOSMOS
Product source

Current GenericRadar decision

Year2034
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2034-12-30
Patent anchor2034-12-30
Exclusivity anchor2026-02-12
Protection date2040-11-13
First Final ANDA—
Status event—

US8598186 corrected c1 trilaciclib structure;PTE1162days from2031-10-25. Crystal/combination tails.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
101898492031-10-25DS —YNTRUE_DS
English description not available.
———
101898492031-10-25ORANGE_BOOK —YNTRUE_DS
English description not available.
———
101898502031-10-25DP —NNDP
English description not available.
———
101898502031-10-25ORANGE_BOOK —NNDP
English description not available.
———
109271202031-10-25DP —NNDP
English description not available.
———
109271202031-10-25ORANGE_BOOK —NNDP
English description not available.
———
110400422031-10-25DP —NNDP
English description not available.
———
110400422031-10-25ORANGE_BOOK —NNDP
English description not available.
———
85981972031-10-25DS/DP —YNTRUE_DS
English description not available.
———
85981972031-10-25ORANGE_BOOK —YNTRUE_DS
English description not available.
———
99572762031-10-25DS —YNTRUE_DS
English description not available.
———
99572762031-10-25ORANGE_BOOK —YNTRUE_DS
English description not available.
———
100859922034-03-14U U-3081NNU
English description not available.
———
100859922034-03-14ORANGE_BOOK U-3081NNU
English description not available.
———
109669842034-03-14U U-3079NYU
English description not available.
———
109669842034-03-14U U-3080NYU
English description not available.
———
109669842034-03-14ORANGE_BOOK U-3079;U-3080NYU
English description not available.
———
117175232034-03-14U U-3679NYU
English description not available.
———
117175232034-03-14U U-3678NYU
English description not available.
———
117175232034-03-14ORANGE_BOOK U-3678;U-3679NYU
English description not available.
———
94875302034-03-14U U-3079NNU
English description not available.
———
94875302034-03-14U U-3080NNU
English description not available.
———
94875302034-03-14ORANGE_BOOK U-3079;U-3080NNU
English description not available.
———
85981862034-12-30DS/DP —YNTRUE_DS
English description not available.
———
85981862034-12-30ORANGE_BOOK —YNTRUE_DS
English description not available.
———
125277982037-12-05U U-3504NNU
English description not available.
———
125277982037-12-05ORANGE_BOOK U-3504NNU
English description not available.
———
115293522039-07-23U U-3504NNU
English description not available.
———
115293522039-07-23ORANGE_BOOK U-3504NNU
English description not available.
———
121686662040-11-13DS/DP —NNDP
English description not available.
———
121686662040-11-13ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2021-02-122026-02-12English description not available.YY2026-02-12—Source
NCE2021-02-122026-02-12English description not available.YY2026-02-12
NCE
Full coverage date: 2026-02-12
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
ANNUAL_DECISION_RECHECK—ANCHOR_AND_TAILUS8598186 corrected c1 trilaciclib structure;PTE1162days from2031-10-25. Crystal/combination tails.Source
Decision history
CurrentYearStatusReviewAnchorJudged
Y2034DEEP_REVIEWFINAL2034-12-302026-10-17 20:32:21
N2034DEEP_REVIEWFINAL2034-12-302026-10-15 05:56:56
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.